1FW /614

Attorney Docket No. 17811US01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

PATENT APPLICATION OF:) <u>Certificate of Mailing</u>
NICOLAS PETER SHORTIS	I hereby certify that this correspondence is being deposited with the United States
U.S. SERIAL NO. 10/588,558	 Postal Service as first class mail, postage prepaid, in an envelope addressed to: Mail Stop Amendment, Commissioner
FILING DATE: August 4, 2006) for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on December 7, 2006.
FOR: USE OF AMINOSALICYLATES IN)
DIARRHOEA-PREDOMINENT	$)$ // \sim 1.
IRRITABLE BOWEL SYNDROME) Thach Ol. Dich
) Jonathan R. Sick
	Registration No. 43,920
GROUP ART UNIT:	Attorney for Applicants
EN AMINICO NI A A A A A A A)
EXAMINER: Not yet assigned.	Customer No. 23446

INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

DEC 1 1 2006

Applicant submits herewith form PTO/SB/08A listing the cited references. Applicant also submits herewith a copy of each of the foreign documents and other publications cited, for consideration by the U.S. Patent and Trademark Office in connection with the above application.

Also submitted herewith is a copy of the International Preliminary Report on Patentability issued on January 11, 2006, in connection with International Application No. PCT/AU2005/000142, which corresponds to the present U.S. application.

This Information Disclosure Statement is being submitted before receipt of a first Office Action on the merits of the application.

Please charge any fees incurred in connection with this submission to Deposit Account No. 13-0017 in the name of McAndrews, Held & Malloy, Ltd.

Respectfully submitted,

Jonathan R. Sick

Registration No. 43,920 Attorney for Applicants

McANDREWS, HELD & MALLOY, LTD. 500 West Madison Street, 34th Floor Chicago, Illinois 60661 Telephone (312) 775-8000 Facsimile (312) 775-8100

Dated: December 7, 2006

PTO/SB/08A (08-03)

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Number

Under the Paperwork Reduction act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449A/PTO Complete if Known **Application Number** 10/588,558 INFORMATION DISCLOSURE Filing Date August 4, 2006 STATEMENT BY APPLICANT **First Named Inventor** Nicolas Peter Shortis (use as many sheets as necessary) **Group Art Unit Examiner Name Attorney Docket** 17811US01

U.S. PATENT DOCUMENTS					
Examiner Initial*	Cite No. ¹	Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	A1	5,519,014	05-21-1996	Borody	
	A2	6,326,364	12-04-2001	Lin, et al.	
	A3	4,556,552	12-03-1985	Porter, et al.	
	A4	4,704,295	11-03-1987	Porter, et al.	

1

of

FOREIGN PATENT DOCUMENTS						
		Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	
Examiner Initials*	Cite No. 1	Country Code ³ -Number ⁴ -Kind Code ⁶ (if known)	Publication Date MM-DD-YYYY			T ⁶
	A5	AU9187301	05-20-1992	Borody		
	A6	WO 1992/016206A	10-01-1992	Norwich Eaton Pharmaceuticals Inc.		
	A7	WO 1992/016214A	10-01-1992	Norwich Eaton Pharmaceuticals Inc.		

OTHER ART NON PATENT LITERATURE DOCUMENTS				
training City item (book, maga		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
A8 PARDI, D.S. et al., "Treatment of Inflammatory Bowel Disease in the Elderly: An Update" Drugs & Aging, (2002) pp. 355-363, Vol. 19, No. 5				
in patients with inflammatory bowel disease intolerant or allergic to sulphasalaz		GIAFFER, M.H. et al., "Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine" Alimentary Parmacology & Therapeutics (1992), pp. 51-59, Vol. 6, No. 1		
A10 STEIN, R.B. et al., "Comparative Tolerability of Treatments for Inflammatory Bowel Discourse Drug Safety, (2000) pp. 429-448, Vol. 23, No. 5		STEIN, R.B. et al., "Comparative Tolerability of Treatments for Inflammatory Bowel Disease" Drug Safety, (2000) pp. 429-448, Vol. 23, No. 5		
		W. KRUIS, "A comparison of two different doses of balsalazide and one dose of mesalazine in chronic treatment of ulcerative colitis" Gastroenterology (1998), p. A1014, Vol. 114		

EXAMINER	DATE CONSIDERED	
SIGNATURE		

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \[^1\text{Applicant's unique citation designation number (optional).}\]^2\text{See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.}\]^3\text{Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).}\]^4\text{For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.}\]^5\text{Kind of document by the appropriate symbols as indicated on the document under WIPO Standard St. 16 if possible.}\]^6\text{Applicant is to place a check mark here if English language Translation is attached.}\]
This collection of information is required to obtain or rathing a rathin

DEC 1 1 2006

Sheet

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.